Studies on the Anticancer and Streptolysin S‐Forming Abilities of Hemolytic Streptococci

Okamoto, Hiroyuki; Shoin, Susumu; Koshimura, Shunichi; Shimizu, Ryusaku

doi:10.1111/j.1348-0421.1967.tb00350.x

Cited by 219 publications

(87 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They examined its tumoricidal effect and prepared heat-killed bacterium of C. liquefaciens isolated from the sternal marrow of the patients with bronchogenic carcinoma, but this was not brought to clinical use. As for preparation of hemolytic streptococci, OK-432 produced by Okamoto et al (1967) has been already used clinically.…”

Section: Discussionmentioning

confidence: 99%

Further observation on empyema after resection of bronchogenic carcinoma and survival.

Sekiguchi

1982

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

cases undergoing resectional therapy for bronchogenic carcioma at 39 institutions, 6,348 were operated before July 1976 and the remaining 4,899 thereafter. Analyzing both series, the following results were obtained: 1) The rate of pneumonectomies to lobectomies was 1:2.3 in the former and 1:3.9 in the latter. Pneumonectomies were more on the left side, whereas the right lobectomies were about twice as many as the left ones. 2) Postoperative empyema occurred in 180 cases (2.8%) in the former and 79 cases (1.6%) in the latter. The incidence was significantly higher in the cases of right pneumonectomy than in the cases of left pneumonectomy, and in the cases of pneumonectomy than in the cases of lobectomy. Although the incidence of postpneumonectomic empyema decreased only slightly, overall incidence decreased significantly because of marked increase of lobectomy cases. 3) Out of 180 cases of empyema in the former series, 17 died within 30 days. 4) The 5-year survival rate of the patients with empyema was 28 per cent. 5) The 5-year survival rate was 30 per cent in 93 cases of squamous cell carcinoma, 30 per cent in 50 cases of adenocarcinoma and 15 per cent in 13 cases of large cell carcinoma. There was no survivor among 7 cases of small cell carcinoma. 6) Out of 259 cases of empyema, micro-organisms were cultured in 161 cases, were negative in 20, and unknown in 78. Although various organisms were found, gram-negative bacteria and Pseudomonas were most frequently isolated, i.e. 37 per cent and 36 per cent, respectively. 7) As for the treatment of 5-year survival cases of empyema, thoracoplasty and bronchial closure were frequent as compared with open thoracic window technics such as Eloesser's and Symbas' operation. And, more than half of the cases of empyema seem to have been complicated with bronchial fistulae.-pneumonectomy; lobectomy; postoperative empyema; bronchogenic carcinoma; survival rateIn 1976 the first cooperative study was performed to examine the results of patients with postoperative empyema. By analysing 6,349 cases of pulmonary resection at 48 institutions up to 1975, the following results were obtained : 1) The rate of pneumonectomies to lobectomies was 1:2.5 and pneumonectomies were more on the left side, whereas the right lobectomies were about twice as many as the left ones. Empyema occurred in 178 cases (2.8%). The incidence was significantly higher in the cases of pneumonectomy than in the cases of lobectomy, and in the cases of right pneumonectomy than in the cases of left one. Out of 114 patients with empyema before 1971, 15 died within 30 days. The 5-year

show abstract

Section: Discussionmentioning

confidence: 99%

Further observation on empyema after resection of bronchogenic carcinoma and survival.

Sekiguchi

1982

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…The strategy to perform "optimization" of DCs in Th1-inducing type by processing DCs ex vivo should be reasonable. We have reported that DCs stimulated with a streptococcal immune adjuvant OK-432 which has been developed in Japan 1970' [12] , produce IL-12, induce Th1-dominant state, and elicit anti-tumor effect, that these effects are more powerful than those of the known DC-maturating factors such as tumor necrosis factor (TNF)-and LPS, and that these reactions are caused via Toll-like receptor signaling ( Figure 1B) [13][14][15][16][17] . A Th1-inducing type of DC vaccine, Vaccell is made as follows.…”

Section: A Japanese DC Vaccine "Vaccell"mentioning

confidence: 99%

Dendritic cell-based vaccine for pancreatic cancer in Japan

Okamoto

Kobayashi

Yonemitsu

et al. 2016

WJGPT

View full text Add to dashboard Cite

Abstract"Vaccell" is a dendritic cell (DC)-based cancer vaccine which has been established in Japan. The DCs play central roles in deciding the direction of host immune reactions as well as antigen presentation. We have demonstrated that DCs treated with a streptococcal immune adjuvant OK-432, produce interleukin-12, induce Th1-dominant state, and elicit anti-tumor effects, more powerful than those treated with the known DCmaturating factors. We therefore decided to mature DCs by the OK-432 for making an effective DC vaccine, Vaccell. The 255 patients with inoperable pancreatic cancer who received standard chemotherapy combined with DC vaccines, were analyzed retrospectively. Survival time of the patients with positive delayed type hypersensitivity (DTH) skin reaction was significantly prolonged as compared with that of the patients with negative DTH. The findings strongly suggest that there may be "Responders" for the DC vaccine in advanced pancreatic cancer patients. We next conducted a smallscale prospective clinical study. In this trial, we pulsed HLA class Ⅱ-restricted WT1 peptide (WT1-Ⅱ) in addition to HLA class Ⅰ-restricted peptide (WT1-Ⅰ) into the DCs. Survival of the patients received WT1-Ⅰ and -Ⅱ pulsed DC vaccine was significantly extended as compared to that of the patients received DCs pulsed with WT1-Ⅰ or WT1-Ⅱ alone. Furthermore, WT1-specific DTH positive patients showed significantly improved the overall survival as well as progressionfree survival as compared to the DTH negative patients. may be associated with a good clinical outcome in advanced pancreatic cancer. We are now planning a pivotal study of the Vaccell in appropriate protocols in Japan.

show abstract

“…OK-432 is a preparation of Streptococcus pyogenes, type A3, which was developed in Japan as an immunotherapeutic agent for cancer [4]. Pleurodesis with OK-432 has been reported to be efficacious for controlling malignant pleural effusions [5,6].…”

mentioning

confidence: 99%

Efficacious pleurodesis with OK‐432 and doxorubicin against malignant pleural effusions

Kishi

Homma²,

Sakamoto³

et al. 2004

Eur Respir J

View full text Add to dashboard Cite

Malignant pleural effusion develops frequently in patients with advanced lung cancer. Chemical pleurodesis is the most effective palliative treatment for these patients.The efficacy of pleurodesis using both OK-432, a preparation of Streptococcus pyogenes, and doxorubicin for 20 patients with cytology-proven malignant pleural effusion associated with lung cancer was evaluated. After complete removal of pleural effusion, OK-432 and 30 mg of doxorubicin were injected via an inserted chest tube. Treatment was terminated when the volume of daily drainage reached v200 mL. If the daily volume remainedw200 mL, an additional OK-432 was administered every 3 days.In total, 16 patients (80%) revealed a complete response, two patients (10%) revealed a partial response, and no response was seen in two patients. Eighteen patients with complete or partial responses did not show subsequent reaccumulation of pleural effusion after pleurodesis. The chest tube remained in place for an average of 6.4 days, draining a mean of 2,854 mL. The main side-effects were fever and pain that were easily treated with nonsteroidal anti-inflammatory drugs.Pleurodesis using both OK-432 and doxorubicin showed high efficacy for controlling malignant pleural effusions caused by lung cancer.

show abstract

Studies on the Anticancer and Streptolysin S‐Forming Abilities of Hemolytic Streptococci

Cited by 219 publications

References 32 publications

Further observation on empyema after resection of bronchogenic carcinoma and survival.

Further observation on empyema after resection of bronchogenic carcinoma and survival.

Dendritic cell-based vaccine for pancreatic cancer in Japan

Efficacious pleurodesis with OK‐432 and doxorubicin against malignant pleural effusions

Contact Info

Product

Resources

About